Health and Medical News and Resources

General interest items edited by Janice Flahiff

Accelerating Medicines Partnership – National Institutes of Health (NIH)

Accelerating Medicines Partnership – National Institutes of Health (NIH)

Great component – sharing data! Note below the bolded underlined portion

From the 4 March 2014 press release

The Accelerating Medicines Partnership (AMP) is a bold new venture between the NIH, 10 biopharmaceutical companies and several non-profit organizations to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets of disease. The ultimate goal is to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them.

AMP will begin with three to five year pilot projects in three disease areas:

For each pilot, scientists from NIH and industry have developed research plans aimed at characterizing effective molecular indicators of disease called biomarkers and distinguishing biological targets most likely to respond to new therapies.

Through this cross-sector partnership, which will be managed through the Foundation for the NIH (FNIH), NIH and industry partners are sharing expertise and resources — $230 million — in an integrated governance structure that enables the best informed contributions to science from all participants. A critical component of the partnership is that industry partners have agreed to make the AMP data and analyses publicly accessible to the broad biomedical community. These pilot projects will set the stage for broadening AMP to other diseases and conditions.

AMP Partners

Government Industry Non-Profit Organizations
FDA

NIH

AbbVie

Biogen Idec

Bristol-Myers Squibb

GlaxoSmithKline

Johnson & Johnson

Lilly

Merck

Pfizer

Sanofi

Takeda

Alliance for Lupus Research

Alzheimer’s Association

American Diabetes Association

Lupus Foundation of America

Lupus Research Institute

Foundation for the NIH

Geoffrey Beene Foundation

PhRMA

Rheumatology Research Foundation

USAgainstAlzheimer’s

Budget: 5 years [$230 Million (Rounded) Total Project Funding]

($Millions) Total Project Total NIH Total Industry
Alzheimer’s Disease 129.5 67.6 61.9
Type 2 Diabetes 58.4 30.4 28
Rheumatoid Arthritis and Lupus 41.6 20.9 20.7
Total 229.5 118.9 110.6

 

Enhanced by Zemanta
Advertisements

March 13, 2014 - Posted by | Medical and Health Research News | , , , , , , , , , , , ,

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: